Back to top
more

Aurinia Pharmaceuticals (AUPH)

(Delayed Data from NSDQ)

$5.12 USD

5.12
1,012,638

-0.04 (-0.78%)

Updated May 7, 2024 04:00 PM ET

After-Market: $5.12 0.00 (0.00%) 6:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AUPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Aurinia Pharmaceuticals Inc [AUPH]

Reports for Purchase

Showing records 41 - 60 ( 136 total )

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 41

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for AUPH

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 42

08/18/2021

Daily Note

Pages: 5

Two Novel Assets Provide an Innovative Pipeline and Creates a More Balanced Corporate Profile; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 43

08/09/2021

Company Report

Pages: 8

2Q Recap: Strong Early Momentum With Top-Line Beat on First Full Quarter of LUPKYNIS Sales

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 44

08/06/2021

Company Report

Pages: 3

2Q-2021 RESULTS

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 45

06/25/2021

Daily Note

Pages: 4

With MAA Filing, Voclosporin Poised to Launch in the EU in Mid-2022; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 46

05/24/2021

Daily Note

Pages: 3

Positive Two-Year LUPKYNIS Data at EULAR, While Some Competitors Stumble; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 47

05/21/2021

Company Report

Pages: 3

Double Bonus -AURORA 2 Interim Results

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 48

05/07/2021

Company Report

Pages: 3

Following approval of Lupkynis on January 22, partial first quarter sales were $0.9 MM.

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 49

05/07/2021

Company Report

Pages: 8

1Q21 Recap: We Remain Confident in LUPKYNIS Uptake, Despite Launch Quarter Consensus Miss From Waning COVID Impacts

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 50

04/08/2021

Daily Note

Pages: 4

LUPKYNIS Improves Renal Response in LN Patients of Various Disease States in Post-hoc Analysis; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 51

03/15/2021

Daily Note

Pages: 3

ICER Report Highlights Favorable LUPKYNIS Cost-Effectiveness Profile; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 52

02/25/2021

Company Report

Pages: 5

4Q20 Recap: Within First Month of Launch and LUPKYNIS Already a Bit Ahead of Expectations; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 53

01/25/2021

Company Report

Pages: 4

We rate shares a ACCUMULATE

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 54

01/25/2021

Company Report

Pages: 6

The Approval of LUPKYNIS Is a Watershed Event in the Treatment of Lupus Nephritis; Raise PT to $35

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 55

12/18/2020

Company Report

Pages: 6

Ex-U.S. Rights Licensed to Otsuka; Competitive Fears Overblown; Raise PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 56

12/18/2020

Industry Report

Pages: 40

2021 Top Ideas-Healthcare Sector Review/Preview

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 75.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 57

12/16/2020

Industry Report

Pages: 39

2021 Top Ideas

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 75.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 58

12/16/2020

Daily Note

Pages: 3

Lonza Deal Signals Strong Confidence in the Long- Term Growth Trajectory of Voclosporin; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 59

11/11/2020

Company Report

Pages: 8

3Q Recap: All-in Focus on Launch Readiness Ahead of January 22 PDUFA

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 60

11/03/2020

Daily Note

Pages: 3

VOS Comes up Dry (LN remains Attractive but AUPH less Diversified).

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party